News

Cytori Receives Positive European Opinion on Scleroderma Orphan Drug Status

Cytori Therapeutics, Inc. recently announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has given a positive opinion concerning Cytori’s submission for an orphan drug designation for ECCS-50, the company’s experimental Scleroderma therapeutic, which is based on stromal vascular fraction cells, from adipose tissue and derived from Celution® System,…

Clinical Trial is Testing Stem Cells in Scleroderma

Richard Burt, MD, of Northwestern University is looking to harness the power of autologous, patient-derived stem cells for the treatment of systemic sclerosis. His previous work in a clinical trial with scleroderma motivated a new phase 3 clinical trial, entitled “…

Scleroderma Damage in Hands Better Assessed with Ultrasonographic Scans

New research on musculoskeletal ultrasound (MSUS) hand features in systemic sclerosis (SSc) or scleroderma and rheumatoid arthritis (RA) entitled “A comparative study between ultrasonographic hand features in systemic sclerosis and rheumatoid arthritis patients: Relation to disease activity, clinical and radiological findings” was recently published in the…

Clinical Phase I/II Pilot Trial Will Study New Therapy for Systemic Sclerosis

Children’s Hospital Los Angeles is recruiting Refractory Systemic Sclerosis Patients between 8 to 18 years of age for a Phase I/II pilot trial of the drug Campath-1H (ClinicalTrials.gov identifier: NCT01639573) to address whether prolonged administration of the drug can result in immunoablation. Campath-1H is a trade name…